More results...

More results...

Accelerating access to precision oncology with decentralized MSK solutions 

SOPHiA GENETICS is collaborating with Memorial Sloan Kettering Cancer Center (MSK) to decentralize their advanced precision oncology tools – MSK-ACCESS® for liquid biopsy and MSK-IMPACT® for comprehensive genomic profiling (CGP). By combining the clinical expertise of MSK in cancer genomics, the predictive algorithms of SOPHiA DDMTM, and the power of the global SOPHiA GENETICS network, experts hope to expand access to precision cancer analysis capabilities worldwide.

Presented by: 

 Michael F. Berger, PhD, Co-Director, Marie-Josée & Henry R. Kravis Center for Molecular Oncology, Elizabeth and Felix Rohatyn Chair for Junior Faculty

Chloe Ryder, Product Manager at SOPHiA GENETICS

Disclaimer notice:​
​
The term SOPHIA used by the speaker refers to SOPHiA GENETICS and its products.​
The opinions expressed during this presentation are those of the speaker and may not represent the opinions of SOPHiA GENETICS. SOPHiA GENETICS does not provide support in the validation of custom products for clinical use. SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

Event Date
November 15, 2023 –

Event Type

Webinar

Event Location

North America

Areas of Interest

Liquid Biopsy, CGP, Oncology

Join the event
pink dots icon

Want to know more?
Get in touch with us.

Our client services team is on hand to help.
';